Bragar Eagel & Squire, P.C., a nationally recognized stockholder law firm, has launched an investigation into whether the board members of Audentes Therapeutics, Inc. (NASDAQ:BOLD) breached their fiduciary duties or violated the federal securities laws in connection with the company’s proposed sale to Astellas Pharma Inc.
Click here to learn more and participate in the action.
On December 2, 2019, Audentes announced that it had signed an agreement to be acquired by Astellas for $60 per share in cash, or a total of approximately $3 billion. The deal is scheduled to close in the first quarter of 2020.
On December 16, 2019, Astellas Pharma commenced the tender offer to acquire Audentes, and the Company filed a statement with the SEC recommending Audentes shareholders to tender their shares. The tender offer is scheduled to expire on January 14, 2020.
Bragar Eagel & Squire is concerned that Audentes’ board of directors oversaw an unfair process and ultimately agreed to an inadequate deal price. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Audentes stockholders.
If you own shares of Audentes and are concerned about the proposed merger, or you’re interested in learning more about the investigation or your legal rights and remedies, please contact Brandon Walker or Alexandra Raymond by email at email@example.com or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.